From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.

Rapid weight loss affects muscle mass and can increase the risk of osteoporosis. But now there is good news for people taking weight loss medication who may be at risk. A new study indicates that the ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

Global Diabetes Drug Market growth is driven by the rising incidence of diabetes and increasing adoption of innovative treatment solutions.Austin, United States, Feb. 10, 2025 (GLOBE NEWSWIRE) -- ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

Southern California-based supplements brand youtheory®  is proud to announce the launch of its doctor-formulated GLP-1 Support line of multivitamins, probiotics and protein powder, now available at ...

The temperature monitoring systems market valued at US$ 3.80 Billion in 2023, is forecasted to grow at a robust CAGR of 5.3%, reaching US$ 4.15 Billion in 2024 and an impressive US$ 5.66 Billion by ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.